{"id":138781,"date":"2018-04-09T10:14:38","date_gmt":"2018-04-09T10:14:38","guid":{"rendered":"https:\/\/stg.strategist1trial.com\/ensayo-strategist3\/"},"modified":"2025-09-15T18:12:29","modified_gmt":"2025-09-15T18:12:29","slug":"ensayo-strategist3","status":"publish","type":"page","link":"https:\/\/stg.strategist3trial.com\/es\/","title":{"rendered":"Ensayo StrateGIST3"},"content":{"rendered":"

[vc_row row_height_percent=\u00bb100″ back_color=\u00bbcolor-138503″ back_image=\u00bb112255″ back_repeat=\u00bbno-repeat\u00bb back_attachment=\u00bbscroll\u00bb back_position=\u00bbcenter center\u00bb parallax=\u00bbyes\u00bb overlay_alpha=\u00bb50″ gutter_size=\u00bb4″ column_width_percent=\u00bb100″ shift_y=\u00bb0″ z_index=\u00bb0″ enable_bottom_divider=\u00bbdefault\u00bb bottom_divider_inv=\u00bbtilt\u00bb shape_bottom_invert=\u00bbyes\u00bb shape_bottom_flip=\u00bbyes\u00bb shape_bottom_h_use_pixel=\u00bb\u00bb shape_bottom_height=\u00bb100″ shape_bottom_color=\u00bbcolor-681992″ shape_bottom_opacity=\u00bb100″ shape_bottom_index=\u00bb0″ medium_visibility=\u00bbyes\u00bb mobile_visibility=\u00bbyes\u00bb el_class=\u00bbgradient\u00bb uncode_shortcode_id=\u00bb821871″ back_color_type=\u00bbuncode-palette\u00bb shape_bottom_color_type=\u00bbuncode-palette\u00bb row_name=\u00bbiphone\u00bb][vc_column column_width_use_pixel=\u00bbyes\u00bb position_vertical=\u00bbbottom\u00bb align_horizontal=\u00bbalign_center\u00bb gutter_size=\u00bb3″ expand_height=\u00bbyes\u00bb style=\u00bbdark\u00bb overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb7″ align_mobile=\u00bbalign_center_mobile\u00bb mobile_width=\u00bb0″ css_animation=\u00bbbottom-t-top\u00bb animation_delay=\u00bb200″ width=\u00bb1\/1″ uncode_shortcode_id=\u00bb177675″ column_width_pixel=\u00bb1000″][vc_empty_space empty_h=\u00bb5″][vc_single_image media=\u00bb138431″ media_width_percent=\u00bb36″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb624267″][vc_column_text text_color=\u00bbcolor-jevc\u00bb uncode_shortcode_id=\u00bb137548″ text_color_type=\u00bbuncode-palette\u00bb]El IDRX-42 (GSK6042981) es un inhibidor altamente selectivo y potente de la prote\u00edna KIT, que es hiperactiva en muchas personas con GIST, lo que provoca el crecimiento y la acumulaci\u00f3n de las c\u00e9lulas cancerosas.[\/vc_column_text][\/vc_column][\/vc_row][vc_row row_height_percent=\u00bb100″ back_color=\u00bbcolor-138503″ back_image=\u00bb112267″ back_repeat=\u00bbno-repeat\u00bb back_attachment=\u00bbfixed\u00bb back_position=\u00bbcenter top\u00bb overlay_alpha=\u00bb50″ gutter_size=\u00bb4″ column_width_percent=\u00bb100″ shift_y=\u00bb0″ z_index=\u00bb0″ enable_bottom_divider=\u00bbdefault\u00bb bottom_divider_inv=\u00bbtilt\u00bb shape_bottom_invert=\u00bbyes\u00bb shape_bottom_h_use_pixel=\u00bb\u00bb shape_bottom_height=\u00bb100″ shape_bottom_color=\u00bbcolor-681992″ shape_bottom_opacity=\u00bb100″ shape_bottom_index=\u00bb0″ desktop_visibility=\u00bbyes\u00bb mobile_visibility=\u00bbyes\u00bb row_name=\u00bbiphone\u00bb el_class=\u00bbgradient\u00bb uncode_shortcode_id=\u00bb159258″ back_color_type=\u00bbuncode-palette\u00bb shape_bottom_color_type=\u00bbuncode-palette\u00bb][vc_column column_width_use_pixel=\u00bbyes\u00bb position_vertical=\u00bbmiddle\u00bb align_horizontal=\u00bbalign_center\u00bb gutter_size=\u00bb3″ style=\u00bbdark\u00bb overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb7″ align_mobile=\u00bbalign_center_mobile\u00bb mobile_width=\u00bb0″ css_animation=\u00bbbottom-t-top\u00bb animation_delay=\u00bb200″ width=\u00bb1\/1″ uncode_shortcode_id=\u00bb276875″ column_width_pixel=\u00bb1000″][vc_empty_space empty_h=\u00bb1″][vc_single_image media=\u00bb138431″ media_width_percent=\u00bb45″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb927066″][vc_empty_space empty_h=\u00bb1″][vc_button button_color=\u00bbcolor-681992″ border_width=\u00bb0″ uncode_shortcode_id=\u00bb321186″ width=\u00bb216″ link=\u00bburl:%23study-description|title:FAQs|\u00bb button_color_type=\u00bbuncode-palette\u00bb]M\u00e1s informaci\u00f3n[\/vc_button][vc_empty_space empty_h=\u00bb2″][vc_column_text text_color=\u00bbcolor-196438″ uncode_shortcode_id=\u00bb111155″ text_color_type=\u00bbuncode-palette\u00bb]Haga clic aqu\u00ed para ver un v\u00eddeo sobre StrateGIST 3, donde se explica el objetivo del estudio, qui\u00e9n puede participar, los medicamentos del estudio y qu\u00e9 esperar durante el mismo.[\/vc_column_text][vc_single_image media=\u00bb123030″ media_width_percent=\u00bb100″ uncode_shortcode_id=\u00bb157773″][\/vc_column][\/vc_row][vc_row row_height_percent=\u00bb100″ back_color=\u00bbcolor-138503″ back_image=\u00bb112266″ back_attachment=\u00bbscroll\u00bb back_position=\u00bbcenter bottom\u00bb parallax=\u00bbyes\u00bb overlay_alpha=\u00bb50″ gutter_size=\u00bb4″ column_width_percent=\u00bb100″ shift_y=\u00bb0″ z_index=\u00bb0″ enable_bottom_divider=\u00bbdefault\u00bb bottom_divider_inv=\u00bbtilt\u00bb shape_bottom_invert=\u00bbyes\u00bb shape_bottom_h_use_pixel=\u00bb\u00bb shape_bottom_height=\u00bb100″ shape_bottom_color=\u00bbcolor-681992″ shape_bottom_opacity=\u00bb100″ shape_bottom_index=\u00bb0″ desktop_visibility=\u00bbyes\u00bb medium_visibility=\u00bbyes\u00bb row_name=\u00bbiphone\u00bb el_class=\u00bbgradient\u00bb uncode_shortcode_id=\u00bb204395″ back_color_type=\u00bbuncode-palette\u00bb shape_bottom_color_type=\u00bbuncode-palette\u00bb][vc_column column_width_use_pixel=\u00bbyes\u00bb position_vertical=\u00bbmiddle\u00bb align_horizontal=\u00bbalign_center\u00bb gutter_size=\u00bb3″ style=\u00bbdark\u00bb overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb7″ align_mobile=\u00bbalign_center_mobile\u00bb mobile_width=\u00bb0″ css_animation=\u00bbbottom-t-top\u00bb animation_delay=\u00bb200″ width=\u00bb1\/1″ uncode_shortcode_id=\u00bb276875″ column_width_pixel=\u00bb1000″][vc_empty_space empty_h=\u00bb1″][vc_single_image media=\u00bb138431″ media_width_percent=\u00bb60″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb482822″][vc_button button_color=\u00bbcolor-681992″ border_width=\u00bb0″ uncode_shortcode_id=\u00bb155178″ width=\u00bb216″ link=\u00bburl:%23study-description|title:FAQs|\u00bb button_color_type=\u00bbuncode-palette\u00bb]M\u00e1s informaci\u00f3n[\/vc_button][vc_empty_space empty_h=\u00bb0″][vc_column_text text_color=\u00bbcolor-196438″ uncode_shortcode_id=\u00bb111155″ text_color_type=\u00bbuncode-palette\u00bb]Haga clic aqu\u00ed para ver un v\u00eddeo sobre StrateGIST 3, donde se explica el objetivo del estudio, qui\u00e9n puede participar, los medicamentos del estudio y qu\u00e9 esperar durante el mismo.[\/vc_column_text][vc_empty_space empty_h=\u00bb0″][vc_single_image media=\u00bb123030″ media_width_percent=\u00bb100″ uncode_shortcode_id=\u00bb157773″][\/vc_column][\/vc_row][vc_row row_height_percent=\u00bb50″ override_padding=\u00bbyes\u00bb h_padding=\u00bb2″ top_padding=\u00bb4″ bottom_padding=\u00bb3″ back_color=\u00bbcolor-681992″ overlay_alpha=\u00bb50″ gutter_size=\u00bb3″ column_width_percent=\u00bb100″ shift_y=\u00bb0″ z_index=\u00bb0″ bottom_divider=\u00bbtilt\u00bb uncode_shortcode_id=\u00bb168548″ back_color_type=\u00bbuncode-palette\u00bb row_name=\u00bbstudy-description\u00bb][vc_column column_width_use_pixel=\u00bbyes\u00bb position_vertical=\u00bbmiddle\u00bb align_horizontal=\u00bbalign_center\u00bb gutter_size=\u00bb3″ overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb0″ mobile_width=\u00bb0″ width=\u00bb1\/1″ column_width_pixel=\u00bb1000″ uncode_shortcode_id=\u00bb145453″][vc_custom_heading text_color=\u00bbcolor-138503″ heading_semantic=\u00bbh1″ desktop_visibility=\u00bbyes\u00bb medium_visibility=\u00bbyes\u00bb mobile_visibility=\u00bbyes\u00bb uncode_shortcode_id=\u00bb671518″ text_color_type=\u00bbuncode-palette\u00bb]\u00bfQu\u00e9 es StrateGIST 3?<\/strong>[\/vc_custom_heading][vc_column_text text_color=\u00bbcolor-xsdn\u00bb uncode_shortcode_id=\u00bb775611″ text_color_type=\u00bbuncode-palette\u00bb]StrateGIST 3<\/strong> es un ensayo cl\u00ednico que prueba un medicamento experimental (medicamento del estudio) llamado IDRX-42 (GSK6042981) en adultos con tumores del estroma gastrointestinal (GIST, por sus siglas en ingl\u00e9s) metast\u00e1sicos y\/o no resecables que han progresado o que no toleraron el tratamiento de primera l\u00ednea con imatinib.<\/span> Los investigadores quieren saber m\u00e1s sobre la seguridad del IDRX-42 (GSK6042981) y comparar sus efectos con el sunitinib, que es un tratamiento aprobado en algunos pa\u00edses para el tipo de GIST que se est\u00e1 estudiando.<\/span> Este ensayo se basar\u00e1 en lo aprendido sobre IDRX-42 (GSK6042981) en un ensayo anterior en personas con GIST.<\/span>[\/vc_column_text][vc_column_text text_color=\u00bbcolor-xsdn\u00bb uncode_shortcode_id=\u00bb246950″ text_color_type=\u00bbuncode-palette\u00bb]El v\u00eddeo a continuaci\u00f3n ofrece una visi\u00f3n general de StrateGIST 3, que incluyen el objetivo del estudio, qui\u00e9n puede participar en \u00e9l, los medicamentos del estudio y qu\u00e9 esperar durante el mismo.[\/vc_column_text][vc_empty_space empty_h=\u00bb3″][vc_button button_color=\u00bbcolor-196438″ border_animation=\u00bbbtn-ripple-out\u00bb border_width=\u00bb0″ display=\u00bbinline\u00bb link=\u00bburl:%23location|title:Join%20the%20Study|\u00bb button_color_type=\u00bbuncode-palette\u00bb width=\u00bb216″ uncode_shortcode_id=\u00bb132884″]Encuentre un centro del ensayo cl\u00ednico[\/vc_button][\/vc_column][\/vc_row][vc_row row_height_percent=\u00bb0″ override_padding=\u00bbyes\u00bb h_padding=\u00bb2″ top_padding=\u00bb7″ bottom_padding=\u00bb7″ back_color=\u00bbcolor-138503″ overlay_alpha=\u00bb50″ gutter_size=\u00bb4″ column_width_percent=\u00bb100″ shift_y=\u00bb0″ z_index=\u00bb0″ enable_top_divider=\u00bbdefault\u00bb top_divider=\u00bbtilt\u00bb shape_top_h_use_pixel=\u00bb\u00bb shape_top_height=\u00bb100″ shape_top_color=\u00bbcolor-681992″ shape_top_opacity=\u00bb100″ shape_top_index=\u00bb0″ enable_bottom_divider=\u00bbdefault\u00bb bottom_divider=\u00bbtilt\u00bb shape_bottom_h_use_pixel=\u00bb\u00bb shape_bottom_height=\u00bb150″ shape_bottom_opacity=\u00bb100″ shape_bottom_index=\u00bb0″ desktop_visibility=\u00bbyes\u00bb medium_visibility=\u00bbyes\u00bb mobile_visibility=\u00bbyes\u00bb uncode_shortcode_id=\u00bb152579″ back_color_type=\u00bbuncode-palette\u00bb shape_top_color_type=\u00bbuncode-palette\u00bb][vc_column column_width_percent=\u00bb100″ gutter_size=\u00bb3″ overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb0″ mobile_width=\u00bb0″ sticky=\u00bbyes\u00bb width=\u00bb1\/2″ uncode_shortcode_id=\u00bb179542″][vc_row_inner limit_content=\u00bb\u00bb][vc_column_inner column_width_percent=\u00bb100″ position_horizontal=\u00bbright\u00bb gutter_size=\u00bb3″ overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb0″ mobile_width=\u00bb0″ width=\u00bb1\/1″ uncode_shortcode_id=\u00bb242247″][vc_custom_heading text_size=\u00bb\u00bb uncode_shortcode_id=\u00bb506177″]\u00bfQu\u00e9 ocurre durante el ensayo?<\/strong>[\/vc_custom_heading][\/vc_column_inner][\/vc_row_inner][vc_column_text uncode_shortcode_id=\u00bb183718″]El ensayo probar\u00e1 el medicamento del estudio, IDRX-42, en adultos con GIST metast\u00e1sico y\/o no resecable que ha progresado mientras tomaban imatinib o que no toleran los efectos secundarios del imatinib. El objetivo es comparar los efectos del IDRX-42 versus el sunitinib.<\/span><\/p>\n

IDRX-42 es un medicamento en investigaci\u00f3n y no ha sido aprobado por ninguna autoridad sanitaria para su uso fuera de un ensayo cl\u00ednico.<\/span>[\/vc_column_text][vc_empty_space empty_h=\u00bb4″][\/vc_column][vc_column column_width_percent=\u00bb95″ gutter_size=\u00bb3″ overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb0″ mobile_width=\u00bb0″ css_animation=\u00bbalpha-anim\u00bb width=\u00bb1\/2″ uncode_shortcode_id=\u00bb900895″][vc_custom_heading text_size=\u00bbh3″ uncode_shortcode_id=\u00bb954054″]Consentimiento informado[\/vc_custom_heading][vc_column_text uncode_shortcode_id=\u00bb195636″]Antes de que decida si desea participar, el equipo del estudio revisar\u00e1 los detalles del ensayo con usted. Esto incluye los posibles riesgos y beneficios, as\u00ed como lo que puede esperar si participa. Si decide participar, le pedir\u00e1n que firme un documento de consentimiento informado. Esto confirma que comprende el ensayo y que est\u00e1 dispuesto a participar para determinar si re\u00fane los requisitos.<\/span>[\/vc_column_text][vc_separator sep_color=\u00bbcolor-prif\u00bb uncode_shortcode_id=\u00bb169390″ sep_color_type=\u00bbuncode-palette\u00bb][vc_custom_heading text_size=\u00bbh3″ uncode_shortcode_id=\u00bb178847″]Selecci\u00f3n[\/vc_custom_heading][vc_column_text uncode_shortcode_id=\u00bb350149″]Para ver si re\u00fane los requisitos, tendr\u00e1 al menos 1 visita al centro del estudio para responder preguntas sobre su salud y los medicamentos que toma, y para someterse a algunas pruebas.<\/span>[\/vc_column_text][vc_separator sep_color=\u00bbcolor-prif\u00bb uncode_shortcode_id=\u00bb169390″ sep_color_type=\u00bbuncode-palette\u00bb][vc_custom_heading text_size=\u00bbh3″ uncode_shortcode_id=\u00bb209503″]Tratamiento del estudio[\/vc_custom_heading][vc_column_text uncode_shortcode_id=\u00bb132873″]Si re\u00fane los requisitos para el ensayo, se le asignar\u00e1 al azar a un grupo para recibir IDRX-42 o sunitinib (el tratamiento aprobado). <\/span><\/p>\n

IDRX-42 se suministra en forma de comprimidos que se toman por v\u00eda oral una vez al d\u00eda en casa. El IDRX-42 se toma todos los d\u00edas. El sunitinib se toma durante 28 d\u00edas seguidos y, a continuaci\u00f3n, se realiza una pausa de 14 d\u00edas (salvo que su m\u00e9dico le indique otra cosa) <\/span>.<\/p>\n

Durante el periodo de tratamiento del estudio, acudir\u00e1 al centro del estudio para comprobar su estado de salud y c\u00f3mo responde su c\u00e1ncer al tratamiento del estudio (IDRX-42 o sunitinib).<\/span><\/p>\n

Si est\u00e1 tomando sunitinib y su c\u00e1ncer empeora, es posible que pueda cambiar a IDRX-42.<\/span><\/p>\n

El promotor del ensayo cl\u00ednico pagar\u00e1 el tratamiento del estudio (IDRX-42 o sunitinib), las visitas y las pruebas relacionadas con el estudio. Se reembolsar\u00e1n los gastos de viaje relacionados con las visitas del estudio.<\/strong>[\/vc_column_text][vc_separator sep_color=\u00bbcolor-prif\u00bb uncode_shortcode_id=\u00bb447472″ sep_color_type=\u00bbuncode-palette\u00bb][vc_custom_heading text_size=\u00bbh3″ uncode_shortcode_id=\u00bb165143″]Seguimiento[\/vc_custom_heading][vc_column_text uncode_shortcode_id=\u00bb435261″]Una vez que usted y su m\u00e9dico decidan interrumpir el tratamiento del estudio, tendr\u00e1 2 visitas m\u00e1s y mantendr\u00e1 llamadas telef\u00f3nicas con el equipo del estudio cada 3 meses.<\/span>[\/vc_column_text][vc_empty_space empty_h=\u00bb2″][vc_button button_color=\u00bbcolor-681992″ border_animation=\u00bbbtn-ripple-out\u00bb border_width=\u00bb0″ uncode_shortcode_id=\u00bb626023″ link=\u00bburl:https%3A%2F%2Fstg.strategist1trial.com%2Ffaqs-2%2F|title:FAQs|\u00bb button_color_type=\u00bbuncode-palette\u00bb]Explore las preguntas frecuentes sobre StrateGIST\u00a03[\/vc_button][vc_empty_space empty_h=\u00bb2″][\/vc_column][\/vc_row][vc_row row_height_percent=\u00bb0″ back_color=\u00bbcolor-138503″ overlay_alpha=\u00bb50″ gutter_size=\u00bb4″ column_width_percent=\u00bb100″ shift_y=\u00bb0″ z_index=\u00bb0″ enable_top_divider=\u00bbdefault\u00bb top_divider=\u00bbtilt\u00bb shape_top_h_use_pixel=\u00bb\u00bb shape_top_height=\u00bb100″ shape_top_color=\u00bbcolor-681992″ shape_top_opacity=\u00bb100″ shape_top_index=\u00bb0″ enable_bottom_divider=\u00bbdefault\u00bb bottom_divider=\u00bbtilt\u00bb shape_bottom_h_use_pixel=\u00bb\u00bb shape_bottom_height=\u00bb150″ shape_bottom_opacity=\u00bb100″ shape_bottom_index=\u00bb0″ uncode_shortcode_id=\u00bb944839″ back_color_type=\u00bbuncode-palette\u00bb shape_top_color_type=\u00bbuncode-palette\u00bb][vc_column column_width_percent=\u00bb100″ align_horizontal=\u00bbalign_center\u00bb gutter_size=\u00bb3″ overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb0″ mobile_width=\u00bb0″ sticky=\u00bbyes\u00bb width=\u00bb1\/1″ uncode_shortcode_id=\u00bb580905″][vc_row_inner limit_content=\u00bb\u00bb][vc_column_inner column_width_percent=\u00bb100″ position_horizontal=\u00bbright\u00bb position_vertical=\u00bbmiddle\u00bb align_horizontal=\u00bbalign_center\u00bb gutter_size=\u00bb3″ overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb0″ mobile_width=\u00bb0″ width=\u00bb1\/1″ uncode_shortcode_id=\u00bb111259″][vc_empty_space empty_h=\u00bb3″][vc_custom_heading text_size=\u00bb\u00bb uncode_shortcode_id=\u00bb506177″]\u00bfQu\u00e9 ocurre durante el ensayo?<\/strong>[\/vc_custom_heading][vc_column_text uncode_shortcode_id=\u00bb105390″]El ensayo probar\u00e1 el medicamento del estudio, IDRX-42 (GSK6042981), en adultos con GIST metast\u00e1sico y\/o no resecable que ha progresado mientras tomaban imatinib o que no toleran los efectos secundarios del imatinib. El objetivo es comparar la seguridad y los efectos del IDRX-42 (GSK6042981) con los del sunitinib.<\/span><\/p>\n

IDRX-42 (GSK6042981) es un medicamento en investigaci\u00f3n y no ha sido aprobado por ninguna autoridad sanitaria para su uso fuera de un ensayo cl\u00ednico.<\/span>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner limit_content=\u00bb\u00bb][vc_column_inner column_width_percent=\u00bb100″ align_horizontal=\u00bbalign_center\u00bb gutter_size=\u00bb3″ overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb0″ mobile_width=\u00bb0″ width=\u00bb1\/1″ uncode_shortcode_id=\u00bb158094″][vc_custom_heading uncode_shortcode_id=\u00bb175823″]Su recorrido en StrateGIST\u00a03[\/vc_custom_heading][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_inner_height_percent=\u00bb0″ overlay_alpha=\u00bb50″ gutter_size=\u00bb3″ shift_y=\u00bb0″ z_index=\u00bb0″ medium_visibility=\u00bbyes\u00bb mobile_visibility=\u00bbyes\u00bb limit_content=\u00bb\u00bb uncode_shortcode_id=\u00bb663441″][vc_column_inner column_width_percent=\u00bb100″ align_horizontal=\u00bbalign_center\u00bb gutter_size=\u00bb3″ overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb0″ mobile_width=\u00bb0″ width=\u00bb1\/1″ uncode_shortcode_id=\u00bb158744″][vc_single_image media=\u00bb139964″ media_width_percent=\u00bb85″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb179949″][vc_single_image media=\u00bb139941″ media_width_percent=\u00bb85″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb208750″][vc_single_image media=\u00bb139918″ media_width_percent=\u00bb85″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb617167″][vc_single_image media=\u00bb139895″ media_width_percent=\u00bb85″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb983685″][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_inner_height_percent=\u00bb0″ overlay_alpha=\u00bb50″ gutter_size=\u00bb3″ shift_y=\u00bb0″ z_index=\u00bb0″ desktop_visibility=\u00bbyes\u00bb limit_content=\u00bb\u00bb uncode_shortcode_id=\u00bb143909″][vc_column_inner width=\u00bb1\/1″][vc_single_image media=\u00bb138551″ media_width_percent=\u00bb85″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb165287″][vc_single_image media=\u00bb138491″ media_width_percent=\u00bb11″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb197707″][vc_single_image media=\u00bb138531″ media_width_percent=\u00bb85″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb840834″][vc_single_image media=\u00bb138491″ media_width_percent=\u00bb11″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb746250″][vc_single_image media=\u00bb112312″ media_width_percent=\u00bb85″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb108810″][vc_single_image media=\u00bb138491″ media_width_percent=\u00bb11″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb121070″][vc_single_image media=\u00bb138511″ media_width_percent=\u00bb85″ alignment=\u00bbcenter\u00bb uncode_shortcode_id=\u00bb868346″][\/vc_column_inner][\/vc_row_inner][vc_empty_space empty_h=\u00bb3″][vc_row_inner limit_content=\u00bb\u00bb][vc_column_inner column_width_percent=\u00bb100″ align_horizontal=\u00bbalign_center\u00bb gutter_size=\u00bb3″ overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb0″ mobile_width=\u00bb0″ width=\u00bb1\/1″ uncode_shortcode_id=\u00bb888870″][vc_button border_width=\u00bb0″ link=\u00bburl:https%3A%2F%2Fstg.strategist1trial.com%2Ffaqs-2%2F|title:FAQs|\u00bb uncode_shortcode_id=\u00bb185672″]FAQs[\/vc_button][vc_empty_space empty_h=\u00bb3″][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=\u00bb0″ override_padding=\u00bbyes\u00bb h_padding=\u00bb2″ top_padding=\u00bb3″ bottom_padding=\u00bb3″ back_color=\u00bbcolor-xsdn\u00bb back_image=\u00bb111788″ parallax=\u00bbyes\u00bb overlay_alpha=\u00bb50″ gutter_size=\u00bb3″ column_width_percent=\u00bb100″ shift_y=\u00bb0″ z_index=\u00bb0″ enable_top_divider=\u00bbdefault\u00bb top_divider=\u00bbtilt\u00bb shape_top_h_use_pixel=\u00bb\u00bb shape_top_height=\u00bb100″ shape_top_opacity=\u00bb100″ shape_top_index=\u00bb0″ enable_bottom_divider=\u00bbdefault\u00bb bottom_divider=\u00bbtilt\u00bb shape_bottom_h_use_pixel=\u00bb\u00bb shape_bottom_height=\u00bb100″ shape_bottom_opacity=\u00bb100″ shape_bottom_index=\u00bb0″ desktop_visibility=\u00bbyes\u00bb medium_visibility=\u00bbyes\u00bb mobile_visibility=\u00bbyes\u00bb uncode_shortcode_id=\u00bb155709″ back_color_type=\u00bbuncode-palette\u00bb row_name=\u00bblocations\u00bb][vc_column column_width_use_pixel=\u00bbyes\u00bb align_horizontal=\u00bbalign_center\u00bb gutter_size=\u00bb3″ overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb0″ mobile_width=\u00bb0″ width=\u00bb1\/1″ uncode_shortcode_id=\u00bb881793″ column_width_pixel=\u00bb900″][vc_empty_space][vc_custom_heading text_size=\u00bb\u00bb uncode_shortcode_id=\u00bb176181″]\u00bfLe interesa obtener m\u00e1s informaci\u00f3n? <\/span>[\/vc_custom_heading][vc_column_text uncode_shortcode_id=\u00bb183639″]Hable con su m\u00e9dico para obtener m\u00e1s informaci\u00f3n y haga clic en el enlace a continuaci\u00f3n para encontrar un centro del ensayo StrateGIST 1 cercano.<\/span>[\/vc_column_text][vc_column_text uncode_shortcode_id=\u00bb654154″]La participaci\u00f3n en el ensayo es voluntaria y puede decidir retirarse en cualquier momento.<\/b>[\/vc_column_text][vc_empty_space empty_h=\u00bb2″][vc_button button_color=\u00bbcolor-773321″ border_animation=\u00bbbtn-ripple-out\u00bb border_width=\u00bb0″ uncode_shortcode_id=\u00bb214268″ link=\u00bburl:https%3A%2F%2Fstg.strategisttrials.com%2Ffaqs%2F|title:FAQs|\u00bb button_color_type=\u00bbuncode-palette\u00bb]Encuentre un centro del ensayo cl\u00ednico[\/vc_button][vc_empty_space empty_h=\u00bb5″][\/vc_column][\/vc_row][vc_row row_height_percent=\u00bb0″ override_padding=\u00bbyes\u00bb h_padding=\u00bb2″ top_padding=\u00bb3″ bottom_padding=\u00bb3″ back_color=\u00bbcolor-xsdn\u00bb overlay_alpha=\u00bb50″ gutter_size=\u00bb3″ column_width_percent=\u00bb100″ shift_y=\u00bb0″ z_index=\u00bb0″ uncode_shortcode_id=\u00bb936538″ back_color_type=\u00bbuncode-palette\u00bb row_name=\u00bblocation\u00bb][vc_column column_width_use_pixel=\u00bbyes\u00bb align_horizontal=\u00bbalign_center\u00bb gutter_size=\u00bb3″ overlay_alpha=\u00bb50″ shift_x=\u00bb0″ shift_y=\u00bb0″ shift_y_down=\u00bb0″ z_index=\u00bb0″ medium_width=\u00bb0″ mobile_width=\u00bb0″ width=\u00bb1\/1″ uncode_shortcode_id=\u00bb881793″ column_width_pixel=\u00bb900″][vc_custom_heading text_size=\u00bb\u00bb uncode_shortcode_id=\u00bb118699″]\u00bfLe interesa obtener m\u00e1s informaci\u00f3n?[\/vc_custom_heading][vc_column_text uncode_shortcode_id=\u00bb125329″]Consulte con su m\u00e9dico para obtener m\u00e1s informaci\u00f3n sobre StrateGIST\u00a03.<\/span><\/p>\n

Tambi\u00e9n puede hacer clic en una ubicaci\u00f3n del mapa de abajo para encontrar un centro StrateGIST\u00a03 cerca de usted. StrateGIST\u00a03 estar\u00e1 disponible en un m\u00e1ximo de 150 centros de ensayos cl\u00ednicos de todo el mundo. Es posible que se abran nuevos centros, por lo que le recomendamos que consulte las actualizaciones.<\/span><\/p>\n

Se reembolsar\u00e1n los gastos de viaje relacionados con las visitas del estudio.<\/span>[\/vc_column_text][\/vc_column][\/vc_row][vc_row row_height_percent=\u00bb0″ override_padding=\u00bbyes\u00bb h_padding=\u00bb2″ top_padding=\u00bb2″ bottom_padding=\u00bb5″ back_color=\u00bbcolor-xsdn\u00bb overlay_alpha=\u00bb50″ gutter_size=\u00bb3″ column_width_percent=\u00bb100″ shift_y=\u00bb0″ z_index=\u00bb0″ uncode_shortcode_id=\u00bb150898″ back_color_type=\u00bbuncode-palette\u00bb][vc_column width=\u00bb1\/1″][vc_column_text uncode_shortcode_id=\u00bb326645″]